Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03477500 (ClinicalTrials.gov)	March 21, 2018	13/2/2018	RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS	Randomized Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab for Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Cyclophosphamide and ATG;Drug: Alemtuzumab	Haukeland University Hospital	NULL	Recruiting	18 Years	50 Years	All	100	Phase 3	Denmark;Netherlands;Norway;Sweden
2	NCT00040482 (ClinicalTrials.gov)	April 1999	26/6/2002	High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis	Intensive Immunosuppression Followed by Rescue With CD34 Selected, T Cell Depleted, Leukopheresis Products in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Cyclophosphamide;Drug: ATG;Drug: MESNA;Procedure: Radiation therapy	Baylor College of Medicine	The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine	Completed	18 Years	60 Years	All	10	Phase 2	United States